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Dr KofidisObjectives: Most tissue-engineering approaches to restore injured heart muscle
result in distortion of left ventricular geometry. In the present study we suggest
seeding embryonic stem cells in a liquid matrix for myocardial restoration.
Methods: Undifferentiated green fluorescent protein–labeled mouse embryonic stem
cells (2  106) were seeded in Matrigel (B&D, Bedford, Mass). In a Lewis rat
heterotopic heart transplant model an intramural left ventricular pouch was fash-
ioned after ligation of the left anterior descending coronary artery. The liquid
mixture (0.125 mL) was injected in the resulting infarcted area within the pouch and
solidified within a few minutes after transplantation (37°C). Five recipient groups
were formed: transplanted healthy hearts (group I), infarcted control hearts (group
II), matrix recipients alone (group III), the study group that received matrix plus
cells (group IV), and a group that received embryonic stem cells alone (group V).
After echocardiography 2 weeks later, the hearts were harvested and stained for
green fluorescent protein and cardiac muscle markers (connexin 43 and -sarco-
meric actin).
Results: The graft formed a sustained structure within the injured area and prevented
ventricular wall thinning. The inoculated cells remained viable and expressed
connexin 43 and -sarcomeric actin. Fractional shortening and regional contractility
were better in animals that received bioartificial tissue grafts compared with control
animals (infarcted, matrix only, and embryonic stem cells only: group I, 17.0% 
3.5%; group II, 6.6%  2.1%; group III, 10.3%  2.2%; group IV, 14.5%  2.5%;
and group V, 7.8%  1.8%).
Conclusions: Liquid bioartificial tissue containing embryonic stem cells constitutes
a powerful new approach to restoring injured heart muscle without distorting its
geometry and structure.
The sequence of events after severe myocardial ischemia caused byobstruction of coronary flow can have detrimental effects on cardiacstructure and function.1 Myocardial cell necrosis is an irreversibleprocess that can ultimately lead to heart failure. Innovative tissue-engineering attempts to reconstitute organ function after a severeinsult promise to diversify our approach to this condition but are
associated with significant limitations. A major limitation is the distortion of cardiac
geometry and structure, a crucial determinant of proper hemodynamic function. The
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suitability as an adequate microenvironment for the inocu-
lated cells represent another limitation. Finally, sensitive
primordial cells with questionable potential to survive in an
area of a lesion constitute a restriction of utmost signifi-
cance.
The heart constitutes a complex helical structure2 with
significant local asymmetry and anisotropy. Variable por-
tions of the left ventricle display distinct mechanical per-
formance and microstructure. The contractions of the par-
ticular elements of all synchronized portions of the ventricle
have to be orchestrated for maximal hemodynamic output.
The vast array of biodegradable materials designed for
implantation into the injured ventricular wall were not des-
tined to achieve such a task.3,4 Furthermore, most of the
used biomaterials constitute single-component isotropic ma-
trices, in which cells are seeded according to the rules of
gravity, resulting in inhomogeneous distribution and there-
fore inconsistent performance throughout the graft; the pe-
riphery of the graft that lies in culture medium or borders
the host tissue is privileged in its blood or nutrient supply,
as opposed to the core of the graft, which is exposed to
severe undersupply conditions.5 The natural sequence of
events is loss of viable donor cells and therefore loss of
function. As a result, the eventual improvement of cardiac
function after replacement of portions of either ventricle is
frequently ascribed to secondary angiogenesis activity trig-
gered by the implanted grafts without clarity as to which
mechanisms mediate such a response (inflammatory or a
targeted paracrine effect).6 A homogeneously populated
graft that would align itself to the intricate geometry of the
remodeling tissue after infarction and would not add to the
load of the diseased area has not yet been introduced.
Moreover, the optimal type of cell to support and retain
the injured region of the heart is still controversial. Common
sense implies that the ideal cell source would be one’s own
body to maximize the likelihood of survival and engraft-
ment of the cells. There is a rich body of work with
autologous bone marrow stem cells and autologous myo-
blasts with variable and questionable success. The lacking
peripheral plasticity of the former and the limited interca-
lation of the latter with their host counterparts restricts their
potential for large-scale sustained myocardial restoration
significantly.
Two recent decisive developments in cell science and mi-
crosurgery might help harness the potential of tissue engineer-
ing and propel efforts to restore myocardium. Of paramount
importance, pluripotent embryonic stem cells (ESCs) isolated
from the embryonic trophoblast have become easy to maintain
and to purify in a more committed state. The remarkable
potential of these cells to self-renew or give rise to a more
differentiated progeny translates into high viability and prom-
ises survival in the hostile environment of an ischemic lesion.
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small animal6 facilitates vigorous manipulations and large-
scale replacement of heart muscle for the most demanding and
complex tissue-engineering approaches, thereby paving the
way for innovative experimentation and circumventing cardio-
pulmonary bypass. Finally, green fluorescent protein (GFP)–
based labeling of donor cells has been introduced to identify
and track the in vivo fate of donor cells.7,8 Simple and reliable
methods of cell labeling before transplantation should be
viewed as an essential part of studies that involve cell or tissue
transfer.
Here we introduce a novel approach to promote recovery
of injured myocardium: we use a liquid compound that
solidifies in vivo for optimal cell seeding and in situ distri-
bution. GFP-labeled ESCs are used as a potential cell sub-
strate in this medium to create bioartificial heart tissue
equivalents. We report on the resulting innovative, robust,
and nondistorting mass transfer for myocardial repair.
Methods
Animal Care
All surgical interventions and animal care were performed in
accordance with the Laboratory Animal Welfare Act, the “Guide
for the Care and Use of Laboratory Animals” (National Institutes
of Health, publication no. 78-23, revised 1978), and the “Guide-
lines and Policies for the Use of Laboratory Animals for Research
and Teaching of the Department of Comparative Medicine,” Stan-
ford University School of Medicine.
Animal Groups
Five groups were formed, each including 5 rats. To design a model
applicable to the future clinical situation, we chose an immuno-
competent syngeneic model that involved Lewis rats as donors and
recipients (Harlan Sprague Dawley, Indianapolis, Ind). In the first
group an undamaged heart was transplanted; in the second group
the donor heart had undergone left anterior descending coronary
artery (LAD) ligation before heterotopic transplantation; in the
third group matrix alone was implanted in a LAD-ligated heart,
which was then heterotopically transplanted; and in the fourth
group the bioartificial cell-Matrigel (B&D, Bedford, Mass) com-
pound was implanted after LAD ligation and heterotopic heart
transplantation. The last group was composed of animals that
received an LAD-ligated heart treated with cell only (without
matrix). The animals were killed, and the hearts were harvested 2
weeks later.
EGFP ES Cells
Polypeptide chain elongation factor 1 (pEF-1) a-enhanced green
fluorescent protein (a-EGFP), which contains the enhanced EGFP
gene under the control of human elongation factor 1 (human EF1),
a promoter, and a neomycin resistance cassette, was constructed as
follows. The promoter region of polycistronic enhanced green
fluorescent protein-N3 (pEGFP-N3) (Clontech, Palo Alto, Calif)
was removed by cutting out the AseI-NheI DNA fragment and
joining blunt-ended termini. Human EF1a promoter from pEF-
BOS (HindIII-EcoRI DNA fragment) was inserted into the HindII-
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a-EGFP by means of electroporation and selected in the presence
of G418. One clone that brightly expresses EGFP was chosen and
used for the experiments. The clone was adapted to feeder-free
conditions and maintained on the gelatin-coated dish in Dulbecco
modified Eagle medium supplemented with 15% fetal calf serum,
2 mmol/L sodium pyruvate, 2 mmol/L L-glutamine, 1 nonessen-
tial amino acids, 0.1 mmol/L 2-mercaptoethanol, 1000 U/mL leu-
cemia inhibitory factor (LIF) (ESGRO, Temecula, Calif), 100
U/mL streptomycin, and 100 g/mL penicillin. Cells were col-
lected after trypsinization with ethylendiamine tetraacetic acid and
placed in aliquots of the same medium as above for inoculation
into Matrigel. One milliliter of growth factor–reduced Matrigel
was maintained in one leg of a Cohesion Y-shaped applicator
(Cohesion, Palo Alto, Calif), and 1 mL of cell suspension that
contained 5  106 GFP-labeled mouse ESCs was maintained in
the second. At the time of injection, the 2 components are mixed,
resulting in a viscous liquid compound that solidifies at 37°C
because of this specific physical property of the vehicle.
Myocardial Injury
Rats were preanesthetized in an isoflurane inhalation chamber and
received an intraperitoneal injection of Ketanest (Ketamin, Park
Davis, Berlin, Germany; 50 mg/kg). Anesthesia was maintained with
inhalational isoflurane for the rest of the procedure (Figure 1, A). We
have used a small animal heterotopic heart transplantation model for
the restorative procedure. Briefly, a median thoracotomy was per-
formed in the donor animal, the LAD was ligated while the heart was
still beating, and a pale demarcated area was identified as a conse-
quence. The heart was flushed with 5 mL of cardioplegic solution
(modified Stanford solution), explanted, and placed on ice. The jelly
compound was prepared before the beginning of the procedure and
maintained in a Y-shaped applicator (Figure 1, A). Two million ESCs
were introduced into one of the 2 legs of the applicator, and Matrigel
was introduced in the other, so that through application of pressure,
the 2 components were mixed in the synthetic tip of the applicator.
The compound was injected (0.125 mL) into the demarcated area, and
the heart was left on ice. A median laparotomy and preparation of the
large intra-abdominal vessels of the recipient followed. The hetero-
topic transplantation was performed as described elsewhere by using
the nonworking heart principle, which involves aortoaortic and pul-
mocaval anastomoses. In this model the ventricles are reperfused
through the coronary circulation; however, they do not eject. This
model is frequently used in transplantation science, and despite the
nonworking classification, there is still vigorous contractility and
fractional shortening present. In various studies this model has been
used for long-term viability studies after transplantation by using
regular palpation of the intra-abdominal graft as an index of graft
integrity.
Echocardiography
Rats were transferred in a portable anesthesia chamber and kept under
2% inhalational isoflurane anesthesia for the duration of the proce-
dure, which took place immediately before the animals were killed.
The abdomen was shaved, and the animals were placed in a recum-
bent position. We used the Acuson Sequoia C256 echocardiography
system (Acuson, Mountain View, Calif) with a 15.8-MHz probe. We
obtained the following measurements: end-systolic diameter (ESD)
The Journal of Thoraciand end-diastolic diameter (EDD) in a cross-section, ESD and EDD at
2 different sites of a longitudinal section of the heart (basal and
apical), posterior wall thickness and septal wall thickness, and calcu-
lated fractional shortening (FS), which was defined as follows:
FS EDDESD ⁄ EDD.
Organ Harvest, Tissue Storage, Immunofluorescence,
and Confocal Microscopy
Hearts were excised and fixed in 2% paraformaldehyde in phos-
phate-buffered saline (PBS) for 2 hours and cryoprotected in 30%
sucrose overnight. Tissue was embedded in OCT medium and
sectioned at 5 m on a cryostat. Serial sections were stained with
hematoxylin and eosin (H&E) or Masson trichrome or used for
immunohistochemistry. For immunohistochemistry, sections were
blocked and incubated with primary antibody for 30 minutes to 1
hour at room temperature. Primary antibodies against cardiac,
immunologic, and GFP proteins were used. These included rabbit
anti-connexin-43, mouse monoclonal anti-sarcomeric actin, mouse
monoclonal anti-smooth smooth muscle actin (Sigma, St Louis,
Mo), goat anti-GFP antibody (Rockland, Gilbertsville, Pa), and
rabbit anti-GFP Alexa-488–conjugated antibody (Molecular
Probes, Eugene, Ore). After brief washing with PBS, sections were
incubated with secondary antibodies for 30 minutes to 1 hour at
room temperature. Texas red–conjugated secondary antibodies or
streptavidin–Texas red was used against the cardiac marker pri-
mary antibodies. Goat anti-GFP antibody was recognized by a
fluorescein isothiocyanate–conjugated secondary antibody. After
brief washing with PBS, sections were mounted with Slowfade
antifade reagent with DAPI (Molecular Probes). Stained tissue was
examined with a Leica DMRB fluorescent microscope and a Zeiss
LSM 510 two-photon confocal laser scanning microscope.
Connexin 43 and -sarcomeric actin were used to identify
differentiation when expressed on donor GFP-positive cells.
Trichrome and H&E stains were used to estimate the extent,
distribution, structure, and kinetics of ensuing scarring after the
infarction and injection of cells; the mode of their organization;
vessel count; and cellular type. H&E was helpful for evaluating
cellular atypia and nuclear polymorphism as indicators of tumor
formation. The trichrome and H&E observations were expressed
on an ordinal scale, ranging from 0 (vessels absent, no scar tissue,
no cellular atypia, no nuclear polymorphism) to 4 (dense vascu-
larization of the optical field corresponding to the GFP-positive
graft, extensive scarring, severe cellular atypia and chaotic pattern,
severe nuclear polymorphism). Therefore the latter findings are to
be regarded as semiquantitative and are represented in the graphs
as scale of the individual event.
Morphometry
Sections were obtained at 5 different levels of the harvested heart.
The infarct was identified as a dark area that contained the injected
GFP conglomerate. For all morphometric evaluations, the focused
microscopic field was photographed with an adapted camera (Di-
agnostic Instruments Inc, Burlingame, Calif). The total GFP-pos-
itive area was measured and related to the infarction area at low
magnification. Five random section of the GFP-positive graft were
photographed and evaluated with Spot advanced software, version
3.4.2 (Diagnostic Instruments Inc), to quantify the extent of ex-
c and Cardiovascular Surgery ● Volume 128, Number 4 573
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ETFigure 1. A, The Y-shaped applicator containing the cell suspension in one leg and Matrigel in the other. Injection
results in immediate homogenous mixing of the 2 compartments. B, Dense populations of GFP-positive donor cells
form robust grafts within injured myocardium as they colocalize with the blue-staining DAPI nuclear signal. C,
Intramural injection of a bioartificial, ESC-containing matrix results in homogenous support of injured myocardium,
with alignment along the collagen fibers. Smooth intermingling of donor (red) and host (blue) collagen structures
between the epicardial (arrowheads) and the endocardial (arrows) portion of the recipient myocardium is seen.
The gaps between the collagen fibers are filled with donor cells in serial alignment. A significant inflammatory
response with massive cell infiltration, foreign-body reaction, and consequent diminishing of the grafted structure
was not observed. D, Matrigel injection without cells also provides structural support without distortion of the left
ventricular wall architecture. The white arrows point at signs of severe ischemia, such as vacuolization and
disintegration of cellular structures. As opposed to the group that received matrix and cells, the Matrigel– host
tissue contact features disruptions, discontinuity, and gap formations around collagen fibers (yellow arrows). E, An
in vivo differentiating progeny of GFP-positive donor cells expresses connexin 43.
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area and the area occupied by the GFP graft on every section
provided an area ratio, which was expressed as a percentage. High
magnification was chosen for this portion of the morphometry
(400) to avoid missing marker-expressing cells.
Statistics
Descriptive statistics included means and SDs of all measured
values. Comparison between 2 study groups was performed with
the Student t test for independent variables (cinetic studies were
performed in separate animal groups) by using Microsoft Excel
2000. Multirange differences were analyzed by means of analysis
of variance with the post hoc Bonferroni test. Statistical analyses
were performed with StatView 5.0 (SAS Institute, Cary, NC).
Results
Engraftment and Restorative Effect
The cells assembled along the Matrigel fibers in large popula-
tions. They were identified as donor cells on the basis of the
GFP signal, which was present 2 weeks after heterotopic
transplantation and injection of the compound (Figure 1, B).
The cell-Matrigel mixture aligned itself along the host organ
structure and geometry, which it did not distort (Figure 1, C).
The implanted collagen inserted well into the surrounding scar
tissue, perpendicular to the host connective tissue structures.
The restorative effect ranged from 30% to 70% of the injured
area, with a mean of 51%  12%. The native margins of the
left ventricular wall were not displaced. Histologically, we
found that GFP-positive cells formed islets or conglomerates
within the infarcted region. Injection of Matrigel without
seeded cells also resulted in structural stabilization and pre-
vented wall thinning (Figure 1, D). The majority of cells did
not assume a cardiomyocyte-like phenotype but expressed the
cardiomyocyte markers connexin 43 and -sarcomeric actin
(Figure 1, E). The cellular distribution of connexin 43 was not
limited to the contact point between GFP-positive cells but
occurred at various points of the cell body. Counting of indi-
vidual cells was not possible because of large surviving pop-
ulations and their conglomerate arrangement. There were only
a few signs of foreign-body reaction because only a few cells
of the lymphocytic phenotype occurred within or around the
graft. Furthermore, no signs of cellular migration beyond the
borders of the scar were noticed. The inoculated cells remained
within the margins of the compound in the infarcted area.
Vessels were evident primarily in the periphery of the com-
pound, in the vicinity of the borders of the graft, and less in the
core of the graft. However, overall cellular density was uni-
form throughout the graft. In the control group with LAD
ligation and no treatment, an extensive scar formed after 2
weeks. In the control group with heterotopic transplantation of
an uninjured heart that received Matrigel without cells, the
graft survived well and was contracting before explantation.
Histologic studies with H&E have revealed only a minor
parenchymal presence of cells of leukocytic origin, without
The Journal of Thoracievidence of graft coronary disease (nude donors and recipi-
ents).
Echocardiographic Evaluation of Cardiac Function
and Contractility
All animals that had undergone LAD ligation displayed
severe posterior wall dyskinesia (ie, the left ventricle as-
sumes a dorsal position in the nonworking heterotopic heart
transplant model using our protocol). Even though the trans-
planted heart does not eject, synchronous wall motion was
obvious. The FS in the treated and control groups was as
follows: group I, 17.0%  3.5%; group II, 6.6%  2.1%;
group III, 10.3%  2.2%; group IV, 14.5%  2.5%; and
group V, 7.8%  1.8%). The ESC-treated group showed
significantly higher FS and regional contractility compared
with the control group with LAD ligation and transplanta-
tion only (14.5%  2.5% vs 6.6%  2.1%; P  .018, t test
for independent variables; Figure 2, A). The group with the
highest FS was the one treated with Matrigel and cells (F 
24; P  .001, post hoc Bonferroni test).
Posterior wall thickness was higher in the same group
(1.5  0.4 mm vs 0.6  0.15 mm, P  .01) compared with
that seen in the infarcted control animals (Figure 2, B).
Septum thickness was also the highest in the ESC-treated
group (1.4  0.2 mm vs 0.9  0.2 mm in the infarcted
control group; F  9.3; P  .01, post hoc Bonferroni test;
Figure 2, B). Left ventricular dilatation was prevented in the
matrix plus ESC–treated group (EDD: 4.1  0.1 mm vs 4.8
 0.4 mm in the group that received no compound; P .03,
t test for independent variables; Figure 2, C). The animals
that received matrix only also experienced prevention of
wall thinning and end-diastolic dilatation. The comparison
of wall thickness and left ventricular cavity dimensions did
not yield significant differences between groups III and IV.
They did not display a significantly better contractility (FS).
The group with ESC only, without matrix, did not experi-
ence improved wall thickness or FS.
Discussion
Injectable bioartificial tissue bears crucial advantages com-
pared with the rigid scaffolds used for myocardial repair.
The quality of these scaffolds is measured by their useful-
ness as ventricular wall support in relation to the goal to be
achieved. Thereby specific physical properties, such as po-
rosity, density, and biodegradability, play a critical role. As
opposed to rigid scaffolds, a Matrigel-based liquid com-
pound does not have to be fixed to the surface of the heart
or at the edges of removed muscle. This aspect prevents
necrosis caused by isolation of core portions of the matrix
from healing elements and blood supply. It contracts within
the scar or injured area perfectly aligned with the surround-
ing tissue. Being liquid at the time of administration allows
for a targeted cell therapy approach, which was not feasible
with preformed or precultured solid scaffolds. Through this
c and Cardiovascular Surgery ● Volume 128, Number 4 575
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can occur in multiple locations, without increasing the sur-
gical trauma to the heart significantly. In contrast, implan-
tation of solid matrices in multiple locations would result in
a severely injurious and lengthy procedure.9-11 Furthermore,
Figure 2. A, FS. In the nonworking but still contractile ventricle of
the transplanted heart, FS was the highest in the matrix plus
ESC–treated group (F  24, *P < .001, post hoc Bonferroni test).
B, Myocardial wall thickness. Posterior wall thickness (PWT) is
higher in the matrix plus ESC–treated group of rats than in the
infarcted control animals (*P  .01, t test for independent vari-
ables). Similarly, septal wall thickness (SWT) was the highest in
the matrix plus ESC–treated group (F  9.3, #P < .01, post hoc
Bonferroni test). C, EDD. Injection of the liquid cell–Matrigel
compound prevents dilatation of the severely damaged left ven-
tricle best compared with that seen in the infarcted group (**P 
.03, t test for independent variables); however, the same effect is
observed in the matrix-only and ESC-only groups. EDD is repre-
sented in millimeters.the use of injectable supporting scaffolds would diminish
576 The Journal of Thoracic and Cardiovascular Surgery ● Octoconcerns of invasiveness, allowing for port access ap-
proaches and targeted transfer at various otherwise unap-
proachable sites of the diseased heart. This advantage is of
paramount importance for the future of the emerging field of
tissue engineering in an era of reduction of surgical trauma
and associated hospitalization. As to the labeling method of
the donor cells, we chose GFP transfection over alternative
techniques (the carboxyfluorescein diacetate succinimidyl
ester method and the membrane fluorescent intercalated dye
pkh26-gl method) because it is clearly superior in terms of
staining intensity and duration. The immunogenic or toxic
effects of GFP have not been fully addressed.
Despite promising reports, it remains controversial how a
rigid scaffold inoculated with undersupplied cells would
participate in or even improve contractility.12,13 Even
though biocompatible scaffolds are known to ignite some
degree of cellular infiltration and angiogenesis, this is most
likely the result of a foreign-body reaction, and there is no
evidence that the immigrating cells are of a muscular phe-
notype or capable of engaging in bridging intercalations
with host contractile elements.14,15 We believe that the
majority of related studies that claim engraftment and func-
tional improvement of the heart with rigid scaffolds must be
viewed with caution as long as they fail to determine the
fate of the inoculated cells and propose secondary angio-
genic events to be the causative mechanism of functional
improvement.
Furthermore, a rigid scaffold lacking self-renewing cells
is unlikely to keep pace with the growing host when used
for the repair of congenital defects. What happens most
likely is a fibrous transformation of the vehicle scaffold, loss
of viable contractile elements, and scar formation. Inject-
able forms of bioartificial tissue might not impair the growth
progress because they assume the host geometry and solid-
ify secondarily in a manner that does not impair the elastic
properties of the injection site. Moreover, injectable bioar-
tificial tissue infiltrates the target organ structure and can be
applied variably at borderline zones between healthy and
diseased regions, thereby bridging dead scar with neighbor-
ing tissue with retained viability and intact metabolism.
This unique property might facilitate migration of primor-
dial cell forms and enhance the healing process. Our data
(Figures 2, B and C) indicate that there is a smooth inter-
mingling of donor and host structures rather than an abrupt
transition. However, both the present and other articles in
the field report significant improvement of cardiac function.
Impressive success with the use of a plethora of cell types
raises the suspicion that functional improvement of the heart
after injury is not attributable to the specific cell type but
rather to the viability support, which is provided by any
transfer of viable matter. All myocardial restoration studies
share a further flaw: by transplanting tissue, compounds,
and cells in a random fashion into the heart muscle without
ber 2004
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do not reproduce cardiac muscle with the highest possible
fidelity. Therefore it needs to be pointed out that fibroblasts
(noncontractile elements) or Matrigel itself could possibly
provide enough structural support to enhance cardiac func-
tion. The present study does not escape this critical point
either. However, it appears clear to the authors that restor-
ative operations in the future will involve minimal invasive
techniques that cause less surgical trauma. Furthermore, a
robust and sustained viability support of the scale provided
by ESCs cannot be achieved with other types of cells, as
shown in a series of studies from our laboratory.16 The
advantage of the principle introduced here (ie, injecting
rather than implanting tissue) offers a restorative approach
that is less invasive than the methods currently used in the
clinic (transplantation and bypass procedures) and the ex-
perimental cardiomyoplastic procedures reported thus far.
An endoscopic application with the appropriate instruments
would be desirable.
The use of injectable bioartificial compounds such as the
one used in our study bears a significant limitation: it allows
only for large-scale intramural support rather than transmural
replacement of the right or left ventricles of the heart. Eschen-
hagen and coworkers17 have used preformed Matrigel-based
constructs for myocardial restoration that had been solid at the
time of implantation. Such constructs would allow for in vitro
preconditioning, including endothelialization. Although this
approach probably constitutes the ultimate endeavor of tissue
engineers, it is certainly unlikely that the injured portion of the
heart can be effectively replaced with a nonbeating or nonvi-
able element after the inoculated cells because of poor vascular
supply. Finally, the liquid phase of our compound facilitates
supplementation of cell suspension with growth factors, heal-
ing promoters, and pharmaceutical substances, for example,
which could be added to promote engraftment and differenti-
ation of the seeded cell population. Matrigel is considered as
basement membrane and generated from Engelbreth-Holm-
Swarm (EHS) sarcoma. Matrigel normally contains not only
basement membrane components (collagens, laminin, and pro-
teoglycans) but also matrix-degrading enzymes, their inhibi-
tors, and growth factors. Invasion of tumor cells into Matrigel
has been used to characterize involvement of extracellular
matrix receptors and matrix-degrading enzymes, which play
roles in tumor progression. For the present study, we used
growth factor/enzyme–reduced Matrigel to minimize the inter-
action of growth factors and ESCs. The use of the Y-shaped
applicator allows for homogenous distribution of any supple-
mental substance within the cellular or Matrigel component
right at the site of instrumentation or surgical intervention.
With the advent of tissue engineering, a plethora of appealing
materials have emerged that could display a better alternative
for restoration of the heart in the future. Matrigel might not be
the material of choice, but at the present time, it offers physical
The Journal of Thoraciadvantages over other types of collagens we and others have
used in the past. It does not disintegrate before administration
(as collagen type I does), it maintains liquid form and solidifies
in vivo, and its growth factor–reduced form does not elicit
severe inflammatory response.
The heterotopic rat heart transplantation model intro-
duced by Krupnik and associates18 is a crucial milestone in
the path to large-scale myocardial restorative procedures.
The advantages of this model range from fiscal to surgical
and are time related. Provided that experienced hands in
transplantation microsurgery are involved, the spectrum of
surgical manipulations with various scaffolds and cells is
almost unrestricted. We chose to injure the heart in an
alternative fashion by ligating the LAD and creating a flap
on the left ventricular surface, allowing for severe tissue
ischemia to take place and simultaneously administering
proportionally high amounts of bioartificial compound to
restore myocardial structure without distorting the left ven-
tricular wall geometry. An isotropic reconstitution of the
myocardial structure is still far from achieved, keeping in
mind that the heart is a complex helical structure with high
regional variability that cannot be imitated with the cur-
rently available scaffolds, neither rigid nor flexible, with
optimal fidelity. However, an intramural implantation of
jelly compound seems to meet the architectonic criteria of
restoration from within more closely. A limitation to our
study is that we did not follow the natural course of infarc-
tion and scar formation for a longer period of time, up to 8
weeks after LAD ligation. Previous experience in our lab-
oratory has shown severe wall thinning in the area of
ischemic injury as early as 2 weeks after injury in rats and
1 week in mice.
A further considerable parameter that is inevitable in this
field is the preimplantation labeling of cells. An insufficient
labeling before inoculation into the scaffold and transplan-
tation limits the potential of distinguishing cell origin. Never-
theless, a rich body of studies lack efficient cell labeling and
tracking methods in the field of tissue engineering. In the
present model cells are GFP labeled and possess a strong
fluorescent signal 2 weeks after implantation. In vivo stud-
ies in our group using mice in a different context demon-
strate undiminished GFP fluorescence in the same cell type
after 8 weeks. A variety of alternative methods of cell
labeling are now also available and have been used effec-
tively on bone marrow stem cells, cardiomyocytes, and
ESCs.19-21
Immunogenicity of the transplanted ESCs might become
a limiting factor in their future clinical use. In preliminary
studies (unpublished data) we found that mouse ESCs are
incredibly robust after injection into the rat heart. We have
carried out several donor-recipient combinations, which all
led to the observation that cyclosporine (INN: ciclosporin)
or the simple allogeneic setting (mouse major mismatch)
c and Cardiovascular Surgery ● Volume 128, Number 4 577
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ETdoes not lead to a significant difference in engraftment and
cell survival. We speculated that ESCs do not have the full
spectrum of surface markers to ignite a multifaceted im-
mune response, even though ESCs are known to express
small amounts of major histocompatibility molecules under
stimulation in the Petri dish. Indeed, cells survived in all
animals within the matrix and also in the group receiving
ESC injection only. Nude rats did not reveal a significant
difference. In a mouse model of ESC transfer, we found
increasing amounts of T-lymphocyte infiltration into the
graft, but it was not significant enough to reduce the size of
the graft, even after 8 weeks (unpublished data).
ESCs and their differentiated derivatives will enter the
field of reconstructive surgery and tissue engineering. Iden-
tifying the mechanisms that drive the mother cell to produce
not only an identical daughter cell but also the cell type that
meets the needs of the surrounding conditions will lead to
the in vivo enhancement of purification of the transplanted
cells, inhibition of tumorigenicity, and improvement of
function. We believe that ESCs have the potential to give
rise to target organ–specific progeny when injected into this
organ. To what extent is not known and is presumably
unpredictable without further manipulation. In our mouse
experiments we have indices of differentiation, as shown in
colocalization studies. In a future study we plan to inject or
transfect cell with factors-genes that are known to drive
cardiomyocyte differentiation (eg, nFAT), along with the
cells and Matrigel.
We did not observe cellular atypia, nuclear polymor-
phism, or teratoma formation in the present model. This
finding does not exclude tumor formation later on in the
postimplantation course. These complex interacting phe-
nomena have not been studied in a bioartificial environment
with restorative intentions yet and were not subjects of the
present study.22-24 Ongoing studies in our laboratory in-
volve premature cardiomyocytes derived from ESCs. How-
ever, only a perfectly (100%) purified population of these
cells will prevent tumor formation in vivo.25,26 This aspect
constitutes a limitation in the present study and is the focus
of ongoing studies.
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